Chimerix Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Good morning, everyone. Good afternoon for those on the East Coast time zone. I'm Mike Sherman, the CEO at Chimerix. I have a story to tell today about a profoundly different company than even 6 months ago. So I look forward to giving you an update on what we're doing at Chimerix.
Probably making far more forward-looking statements than my Investor Relations team would like, so let me point you to our recent SEC filings for a more complete disclosure of those risks and uncertainties.
We say we're focused on delivering real benefit to patients. I'm going to spend just a minute on that point. For those who have experienced a life-threatening disease or cancer, as I have, you'll find that you look at Kaplan-Meier curves a little differently from that side of the equation. A couple of months of progression-free survival or stable disease is not terribly interesting.
When you're talking about diseases like acute myeloid leukemia or smallpox, for that matter, it's really about getting to cures, on a higher cure rate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |